An exciting proof-of-concept study of Lutetium-177 PSMA (Lu PSMA) was published in the journal Lancet Oncology. Lu-PSMA has been described as “a disruptive therapy and has the potential to change practice” in the future treatment of men with end-stage prostate cancer.
Lu-PSMA, a nuclear therapy, has been used in Germany for many years under compassionate use basis. This particular study was conducted in Australia. The study results offer hope for men with end-stage prostate cancer who have exhausted all their treatment options.